Omaha, Nebraska


Email John Inserra
John Inserra
John Inserra
Attorney • (800) 642-1242


Comments Off

As reported in The New England Journal of Medicine, a study shows that rosiglitazone, sold as Avandia by GlaxoSmithKline was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. The study concludes:

patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes